The U.S. FDA approved WAYRILZ (rilzabrutinib) tablets for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded to previous treatments.
MOA: kinase inhibitor
Dosage: 400 mg BD PO
Key Safety Precautions:
- Infections: Monitor closely
- Liver toxicity: Check bilirubin and liver enzymes
- Pregnancy: May cause fetal harm; use contraception
- Drug interactions: Avoid CYP3A inhibitors/inducers, PPIs; take 2 hours before antacids or H2 blockers
- Organ impairment: Not for moderate/severe liver or severe kidney disease
Side Effects: Most common: diarrhea, nausea, headache, abdominal pain, and COVID-19 infection.